Estados financieros detallados de NeuroPace, Inc. (NPCE): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
NeuroPace, Inc. registró ingresos de $100.0M en el último ejercicio fiscal, con un CAGR de 5 años del 19.4%.
Márgenes de los últimos 12 meses: margen bruto 79.6%, margen operativo -15.3%, margen neto -19.3%.
Al precio actual de $14.10, NPCE presenta beneficios negativos (P/E no significativo) y un ROE del -119.68%. La capitalización bursátil es de $481M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | $37.0M | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Coste de Ventas | $10.5M | $10.9M | $11.7M | $13.0M | $17.3M | $20.8M | $22.8M |
| Beneficio Bruto | $26.5M | $30.3M | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| I+D | $18.3M | $15.7M | $18.2M | $21.9M | $20.8M | $23.7M | $27.9M |
| Generales y Administrativos | $30.2M | $27.6M | $39.0M | $51.3M | $54.5M | $57.1M | $65.7M |
| Gastos Operativos | $48.5M | $43.3M | $57.2M | $73.3M | $75.3M | $80.8M | $93.6M |
| Beneficio Operativo | -$22.0M | -$13.1M | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| EBITDA | -$20.1M | -$12.5M | -$28.4M | -$36.6M | -$22.8M | -$16.6M | -$12.1M |
| Gastos por Intereses | $9.5M | $11.5M | $7.4M | $7.5M | $8.5M | $8.8M | $7.5M |
| Beneficio Antes de Impuestos | -$30.0M | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$30.0M | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| BPA | $-2.70 | $-2.17 | $-2.17 | $-1.91 | $-1.27 | $-0.93 | $-0.66 |
| BPA Diluido | $-2.70 | $-2.17 | $-2.17 | $-1.91 | $-1.27 | $-0.93 | $-0.66 |
| Acciones en Circulación (Diluidas) | $11.1M | $11.1M | $16.6M | $24.6M | $25.9M | $29.1M | $32.7M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $4.1M | $26.4M | $19.2M | $6.6M | $18.1M | $13.4M | $21.7M |
| Inversiones a Corto | $969000 | $11.7M | $96.4M | $70.8M | $48.4M | $39.3M | $39.4M |
| Cuentas por Cobrar | $6.0M | $8.4M | $7.1M | $7.5M | $12.3M | $12.9M | $14.7M |
| Inventario | $7.9M | $6.9M | $7.8M | $9.7M | $11.2M | $13.4M | $16.9M |
| Activos Corrientes | $20.3M | $54.6M | $132.8M | $97.7M | $92.7M | $81.3M | $94.1M |
| Inmovilizado Material | $810000 | $515000 | $603000 | $15.9M | $14.4M | $12.9M | $11.3M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $21.1M | $56.0M | $133.6M | $114.1M | $107.7M | $94.6M | $105.6M |
| Cuentas por Pagar | $903000 | $949000 | $1.4M | $2.1M | $2.3M | $3.0M | $2.2M |
| Deuda a Corto | $62.8M | $2.0M | 0 | 0 | 0 | 0 | $2.1M |
| Pasivos Corrientes | $75.1M | $9.6M | $9.3M | $11.0M | $16.2M | $15.2M | $17.8M |
| Deuda a Largo | 0 | $50.8M | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Pasivos Totales | $150.4M | $203.8M | $60.1M | $79.3M | $87.0M | $86.6M | $86.5M |
| Reservas | -$363.6M | -$387.7M | -$423.8M | -$470.9M | -$503.8M | -$531.0M | -$552.4M |
| Patrimonio Neto | -$129.3M | -$147.8M | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
| Deuda Total | $62.8M | $52.9M | $49.8M | $69.8M | $72.4M | $73.3M | $70.8M |
| Deuda Neta | $57.7M | $14.8M | -$65.7M | -$7.6M | $5.9M | $20.6M | $9.8M |
| Capital Circulante | -$54.9M | $45.0M | $123.5M | $86.7M | $76.5M | $66.2M | $76.3M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$30.0M | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Amortizaciones | $421000 | $312000 | $296000 | $3.0M | $1.6M | $1.8M | $1.9M |
| Compensación en Acciones | $1.4M | $1.4M | $4.3M | $8.3M | $9.6M | $10.3M | $11.1M |
| Cambio en Capital Circulante | $9000 | -$2.1M | $368000 | -$4.8M | -$2.5M | -$5.5M | -$4.0M |
| Flujo de Caja Operativo | -$25.0M | -$21.6M | -$24.6M | -$36.9M | -$19.7M | -$17.9M | -$11.0M |
| Inversiones (CapEx) | -$468000 | -$62000 | -$384000 | -$603000 | -$173000 | -$306000 | -$332000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | -$49.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$25.5M | -$21.7M | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +11.3% | +9.8% | +0.7% | +43.7% | +22.1% | +25.1% | |
| Crecimiento Beneficio Neto (anual) | +19.0% | -48.6% | -30.5% | +30.0% | +17.6% | +20.9% | |
| Crecimiento BPA (anual) | +19.6% | +0.0% | +12.0% | +33.5% | +26.8% | +29.0% | |
| Cambio en Acciones (anual) | +0.0% | +49.6% | +48.1% | +5.1% | +12.7% | +12.3% | |
| Crecimiento FCF (anual) | +15.0% | -15.2% | -50.1% | +47.0% | +8.1% | +37.9% | |
| Margen Bruto | 71.6% | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Margen Operativo | -59.6% | -31.7% | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Margen EBITDA | -54.3% | -30.3% | -62.8% | -80.3% | -34.9% | -20.7% | -12.1% |
| Margen Neto | -81.1% | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| Margen FCF | -69.0% | -52.7% | -55.2% | -82.3% | -30.4% | -22.8% | -11.3% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-2.30 | $-1.95 | $-1.50 | $-1.52 | $-0.77 | $-0.63 | $-0.35 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $11.1M | $11.1M | $16.6M | $24.6M | $25.9M | $29.1M | $32.7M |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -119.68% |
| Rentabilidad sobre capital invertido | -18.43% |
| Rentabilidad sobre activos | -19.71% |
| Margen bruto | 79.63% |
| Margen operativo | -15.26% |
| Margen neto | -19.34% |
Salud financiera
| Deuda / Patrimonio | 5.88 |
| Ratio corriente | 4.94 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -2.52 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -9.24 | -11.50 | -4.65 | -0.78 | -8.12 | -12.03 | -23.39 |
| P/VC | -2.14 | -1.87 | 2.28 | 1.05 | 12.90 | 40.67 | 26.55 |
| P/V | 7.50 | 6.74 | 3.71 | 0.81 | 4.07 | 4.08 | 5.05 |
| Margen Bruto | 71.6% | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Margen Operativo | -59.6% | -31.7% | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Margen Neto | -81.1% | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
Empresas relacionadas: ALDX · BWAY · CERS · CVRX · DCTH · GNLX · MASS
Explorar sector: Healthcare · Medical - Devices
Más secciones de NPCE: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones